Tradestie Institutional Equity Comparison Engine · Market Close Aug 03, 2026

KVAC vs TOI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KVAC Captures Overall Composite Edge (58.0 HOLD vs 53.5 HOLD), While TOI Leads 4–1 on Growth & Valuation Pillars

KVAC Overall Winner 6-Pillar Tally: KVAC 1 – 4 TOI (1 Tie) Matrix Metrics: KVAC 5 – 4 TOI

As of Aug 03, 2026, Keen Vision Acquisition Corporation (KVAC) captures the overall head-to-head institutional edge over The Oncology Institute, Inc. (TOI) on higher Unified Composite conviction (58.0/100 HOLD vs. 53.5/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while TOI wins 4–1 across the 6-pillar growth and valuation breakdown. KVAC trades at $11.51 (N/M Forward P/E, 0.0% operating margin) versus TOI at $5.13 (N/M Forward P/E, -4.4% operating margin).

  • Growth vs. Quality Trade-Off: KVAC earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. TOI 53.5/100 HOLD) and -0.17β · 76% Vol risk profile, whereas TOI leads top-line expansion (+41.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KVAC vs TOI
KVAC US Equity Head-to-Head Winner
Keen Vision Acquisition Corporation
Blank Checks
$11.51
-13.13% 1D
Market Cap $73.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.17β · 76% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
TOI NASDAQ
The Oncology Institute, Inc. Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$5.13
+5.56% 1D
Market Cap $506.9M
TTM Revenue $546M
Forward P/E N/M
Beta / 30D Vol 1.66β · 73% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.6 · SMA20: $5.41 · SMA50: $5.16

6-Pillar Scorecard Institutional Category Breakdown (KVAC 1 – 4 TOI)

Columns: Metric · KVAC · TOI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 88.3x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.0x
2. Growth & Scale TOI
Revenue Growth (YoY) +0.0% +41.2%
Earnings Growth (YoY) -76.9% +0.0%
TTM Revenue (USD) N/A $546M
Market Cap $73.0M $506.9M
3. Profitability & Quality KVAC
Gross Margin N/A 15.1%
Operating Margin 0.0% -4.4%
Net Profit Margin 0.0% -8.0%
Return on Equity (ROE) 0.0% -651.7%
4. Balance Sheet & Cash Flow TOI
Cash Generation (TTM) -$429,086 -$3.3M
Cash Flow Margin N/A -0.6%
Net Cash / Leverage $1.6M Net Debt (0.48x D/E) $63M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TOI
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 80.2% (35th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TOI
OpEx & R&D Intensity N/A 19.5% of Rev ($106M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Shell Companies Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KVAC (5) vs TOI (4)
Institutional Metric KVAC TOI Criterion Row Edge
Market Capitalization
Scale
$73.0M $506.9M Larger Scale TOI
Trailing P/E Ratio
Valuation
88.3x N/M Lower Multiple KVAC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +41.2% Higher Growth TOI
Operating Margin (TTM)
Profitability
0.0% -4.4% Higher Margin KVAC
Net Profit Margin
Profitability
0.0% -8.0% Higher Margin KVAC
Return on Equity (ROE)
Capital Efficiency
0.0% -651.7% Higher ROE KVAC
52-Week Range Position
Momentum
0% ($12–$19) 65% ($2–$7) Stronger Trend TOI
Beta / 30D Volatility
Risk Regime
-0.17β · 76% Vol 1.66β · 73% Vol Lower Realized Risk TOI
Unified Institutional Score
Composite Signal
58.0 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite KVAC
Trailing 12M Revenue (USD)
Operating Scale
N/A $546M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 15.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$429,086 ($1.6M Net Debt (0.48x D/E)) -$3.3M ($63M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TOI +12.3 pp
KVAC: -6.42% · TOI: +5.88%
3M Horizon TOI +38.56 pp
KVAC: -2.04% · TOI: +36.52%
6M Horizon TOI +55.59 pp
KVAC: -1.79% · TOI: +53.8%
1Y Horizon TOI +55.59 pp
KVAC: -1.79% · TOI: +53.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KVAC vs TOI. Trailing 12-month operating profitability (KVAC 0.0% vs TOI -4.4%) and valuation multiples (KVAC N/M vs TOI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KVAC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
TOI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$546M
Gross Margin15.1%
Op. Margin-4.4%
ROE / Fwd P/E-651.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TOI SURGE
14d in phase · OBV DISTRIBUTION
Current IV 80.2%
IV Percentile 35th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TOI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KVAC Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $73.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TOI Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $506.9M market capitalization and -4.4% operating margin.
OpEx & R&D Reinvestment 19.5% of Rev ($106M)
90D Engineering Disclosures 0 Published

Investor FAQ KVAC vs TOI Key Questions & Quantitative Answers

As of Aug 03, 2026, Keen Vision Acquisition Corporation (KVAC) captures the overall head-to-head institutional edge over The Oncology Institute, Inc. (TOI) on higher Unified Composite conviction (58.0/100 HOLD vs. 53.5/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while TOI wins 4–1 across the 6-pillar growth and valuation breakdown. KVAC trades at $11.51 (N/M Forward P/E, 0.0% operating margin) versus TOI at $5.13 (N/M Forward P/E, -4.4% operating margin). Growth vs. Quality Trade-Off: KVAC earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. TOI 53.5/100 HOLD) and -0.17β · 76% Vol risk profile, whereas TOI leads top-line expansion (+41.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

TOI leads the Growth & Scale pillar: KVAC posts +0.0% YoY revenue growth and -76.9% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TOI at +41.2% YoY revenue growth and +0.0% YoY earnings growth on $546M TTM revenue (15.1% gross margin, -4.4% operating margin). On trailing 12-month operating scale, KVAC generates N/A in USD-normalized revenue versus $546M for TOI. In operating R&D and SG&A reinvestment, KVAC deploys N/A (0 90-day corporate R&D disclosures) versus 19.5% of Rev ($106M) (0 disclosures) for TOI.

KVAC and TOI trade at balanced relative valuation multiples. KVAC trades at N/M Forward P/E, 88.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TOI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-0.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KVAC (0.0% ROE) versus TOI (-651.7% ROE) capital efficiency.

In options market volatility and institutional positioning, KVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 76% Vol realized risk). By comparison, TOI carries 80.2% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.66β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 03, 2026. For educational research only; not investment advice.